Baseline patient demographics, ocular and disease characteristics (Safety set*)
| Total (N=936) | Unilaterally treated (n=823) | Bilaterally treated (n=113) | |
| Mean (SD) age, years | 78.7 (7.3) | 78.8 (7.4) | 78.1 (6.7) |
| Age category, n (%) | |||
| <65 years | 33 (3.5) | 32 (3.9) | 1 (0.9) |
| 65–74 years | 212 (22.7) | 178 (21.6) | 34 (30.1) |
| 75–84 years | 483 (51.6) | 427 (51.9) | 56 (49.6) |
| ≥85 years | 208 (22.2) | 186 (22.6) | 22 (19.5) |
| Gender, Female, n (%) | 582 (62.2) | 509 (61.9) | 73 (64.6) |
| Race, n (%) | |||
| Caucasian | 935 (99.9) | 822 (99.9) | 113 (100.0) |
| Black | 1 (0.1) | 1 (0.1) | 0 |
| nAMD affected, n (%) | |||
| Unilaterally | 534 (57.1) | 534 (64.88) | 0 |
| Bilaterally | 399 (42.6) | 286 (34.8) | 113 (100.0) |
| Not affected | 3 (0.3) | 3 (0.4) | 0 |
| Age at first diagnosis, years* | |||
| Mean (SD) | 76.6 (7.8) | 76.6 (7.9) | 76.4 (7.2) |
| Age at first diagnosis of the treated eye, years* | |||
| Mean (SD) | 77.1 (7.7) | 77.2 (7.7) | 76.5 (7.2) |
| Time from first diagnosis to informed consent, years† | |||
| Mean (SD) | 2.1 (3.0) | 2.2 (3.1) | 1.7 (1.9) |
| Time from first diagnosis of the treated eye to informed consent, years† | |||
| Mean (SD) | 1.6 (2.3) | 1.6 (2.3) | 1.7 (1.9) |
*Data not available for three patients in the unilaterally treated group.
†Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug and had at least one postbaseline safety assessment.
nAMD, neovascular age-related macular degeneration; VA, visual acuity.